RCI
PYXS icon

Ridgeback Capital Investments’s Pyxis Oncology PYXS Stock Holding History

Ridgeback Capital Investments’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-359,231
Closed -$560K – 1
2024
Q4 		$560K Buy
+359,231
New +$1.04M 100% 1

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ridgeback Capital Investments's PYXS Position: Q1 2025 in Review

Ridgeback Capital Investments sold out of Pyxis Oncology (PYXS) in Q1 2025, closing a stake of 359,231 shares — an estimated $560K sold.

Ridgeback Capital Investments first reported a position in PYXS in Q4 2024 and held it in 1 quarter. The position peaked at $560K in Q4 2024. 88 funds tracked by Wall St. Rank hold PYXS as of Q1 2025.

  • Ridgeback Capital Investments reported no remaining Pyxis Oncology position as of Q1 2025 after selling out during the quarter.
  • Ridgeback Capital Investments sold 359,231 Pyxis Oncology shares in Q1 2025, an estimated $560K.
  • Ridgeback Capital Investments first reported a position in Pyxis Oncology in Q4 2024 and held it in 1 quarter.
  • Ridgeback Capital Investments's Pyxis Oncology position peaked at $560K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2025.

Based on Ridgeback Capital Investments's 13F filing for Q1 2025.